Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

62.5%

5 terminated/withdrawn out of 8 trials

Success Rate

37.5%

-49.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
3(50.0%)
6Total
Phase 2(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT00512148Phase 2Terminated

Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury

Role: lead

NCT00594139Phase 2Withdrawn

Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence

Role: lead

NCT00419120Phase 2Terminated

Augmentation Cystoplasty Using an Autologous Neo-Bladder

Role: lead

NCT02008851Phase 1Terminated

A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes

Role: lead

NCT01846715Phase 1Terminated

Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease

Role: lead

NCT01087697Phase 1Completed

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

Role: lead

NCT00615043Completed

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Role: lead

NCT00577785Completed

Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery

Role: lead

All 8 trials loaded